Canon introduces new combined CT-angiography interventional system

Canon Medical gained U.S. Food and Drug Administration (FDA) clearance for its combined angiography-computed tomography Alphenix 4D CT with Aquilion One/Insight Edition interventional imaging system. The company plans to highlight the system at the Radiological Society of North America (RSNA) 2025 meeting Nov. 30 - Dec. 4, and have it commercially available in the summer of 2026.

The next-generation angio-CT hybrid solution is not just for interventional radiology, but also for neurology, trauma, stroke and pediatrics. It combines the Alphenix Sky+ angiography system with the Aquilion One/Insight Edition CT scanner. It enables diagnosis, planning, treatment and verification all in one room.

"This is an extremely exciting time for Canon as we are leading innovation in interventional radiology. This represents an expansion to reach out beyond interventional radiology into specialties such as pediatrics, trauma and stroke. We found since the release of our current version that the demand for a single room solution for multiple specialties is very high. While we really focused on interventional radiology and interventional oncology, the utility beyond those specialties became in high demand," Jaimin Chung, director of Canon Medical’s interventional X-ray and vascular business unit, explained in an interview with Radiology Business.